|
Key Drug Pipeline Databases on Dialog
Lesson 4:
Adis R&D Insight
(File 107/907)
• Objectives
• About Adis R&D Insight
• Why Adis R&D Insight
• The Record
• Exercises
• Summary
• Glossary
• Print Tips
• About the Icons
Links to Other Lessons:
Technical Help
with Online Courses
Need Help?
E-mail the
|
|
|
|
Lesson 4: Adis R&D Insight (File 107/907)
The Record...
I planned to send Sharon information on ratings from this database, but I'll wait on that. First, I think she will find the nomenclature data comprehensive. She might also need the extensive pharmacology information. I'll just get the entire record.
The first part of the record in Adis R&D Insight includes basic drug data, such as the drug name, company information, and synonyms for the drug as in File 445, IMS R&D Focus, and File 128, Pharmaprojects.
Note that the brand name is in a separate field
similar to IMS's structure. The lab code and other
names are listed under synonyms in Adis as they are
in Pharmaprojects.
This database includes not only the EPhMRA ATC Code (Anatomical Therapeutic Class Codes) but also the ATC Code from the World Health Organization (WHO) making it an important database for healthcare institutions.
Note: In order to give you supplemental information (tips, learn more comments) about the Dialog record, we have had to add spaces between some of the fields. Print out this link of the complete record for File 107 to have a concise duplicate of the Dialog record you will retrieve online. You can compare it to the parts of the record we will highlight later in the lesson.
Here are a few things Sharon might want to see from this part of this record.
- Drug/product name: Adis R&D Insight provides
a broad range of alternative product nomenclature
with drug name, brand name, synonym, chemical name,
and CAS® Registry Number.
- Company name: The company name is a broad label including the originator company, parent company, other companies and licensee company. The file indexes the parent company name for originators not licensees.
- Development status: The developmental
status gives a history of the drug's progress through
phases, registration, and launch in different countries,
with indications included.
Unlike the two databases we just reviewed, File 107 does not have patent information.
Review the bibliographic part of the record and then go to the next page.
5/9/1
DIALOG(R)File 107: Adis R&D Insight
(c) 2007 Adis Data Information BV. All rights reserved.
00240128 012103
Drug Name: Vatalanib
Record Revision Date: 20061229
Synonyms: CGP 79787; PTK 787; PTK/ZK; PTK787; ZK 222584
Chemical Name: 1-(p-chloroanilino)-4-(4-pyridylmethyl)phthalazine
Molecular Formula: C20H15ClN4
CAS Registry Number: 212141-54-3
WHO ATC Code: L01 - Antineoplastic Agents; S01X - Other
Ophthalmologicals
EPHMRA ATC Code: L1 - Antineoplastics; S1X - Other
Ophthalmologicals
Mechanism of Action: Tyrosine kinase inhibitors; Protein kinase
inhibitors; Protein kinase modulators; Phosphotransferase
(Alcohol Group Acceptor) inhibitors; Phosphotransferase
(Alcohol Group Acceptor) modulators; Kinase inhibitors; Kinase
modulators; Transferase inhibitors; Transferase modulators;
Enzyme inhibitors; Enzyme modulators; Vascular endothelial
growth factor antagonists; Angiogenic protein inhibitors;
Protein inhibitors; Peptide antagonists; Growth factor
antagonists; Intercellular signalling peptide and protein
inhibitors; Protein modulators
Originator Company: Bayer Schering Pharma (Germany); Novartis
(Switzerland); M. D. Anderson Cancer Center (USA); Novartis
(USA)
Parent Company: Bayer; M. D. Anderson Cancer Center; Novartis
Licensee: Bayer Schering Pharma; Novartis
Highest Phase: Phase III
Development Status: Phase III, Switzerland, Colorectal cancer
Phase III, USA, Colorectal cancer
Phase II, Switzerland, Age-related macular degeneration
Phase II, Italy, Glioblastoma
Phase II, Netherlands, Glioblastoma
Phase II, France, Non-small cell lung cancer
Phase II, Germany, Non-small cell lung cancer
Phase II, Switzerland, Solid tumours
Phase II, USA , Solid tumours
Phase I, Germany, Colorectal cancer
Phase I, Germany, Glioblastoma
Phase I, Germany, Ovarian cancer
Phase I, Germany, Renal cancer
Phase I, Switzerland, Renal cancer
Preclinical, USA, Multiple myeloma
|
Go to the next page to learn more about the Pharmacology information contained in this record.
4-4
|
|